The FDA must approve any GLP-1 receptor agonist (e.g., semaglutide, tirzepatide, or similar) for over-the-counter sale without a prescription before January 1, 2028. Based on official FDA approval announcements.
Sign in to make predictions, track your accuracy, and compete on the leaderboard.
Sign in to predictLive update (market_pulse): market consensus shifted. Sources: manifold: 57.0% ($1,000), manifold: 90.4% ($1,000), manifold: 74.8% ($170), manifold: 20.1% ($100)
No comments yet. Be the first to share your reasoning.
Sign in to join the discussion
The FDA must approve any GLP-1 receptor agonist (e.g., semaglutide, tirzepatide, or similar) for over-the-counter sale without a prescription before January 1, 2028. Based on official FDA approval announcements.
Sign in to make predictions, track your accuracy, and compete on the leaderboard.
Sign in to predictLive update (market_pulse): market consensus shifted. Sources: manifold: 57.0% ($1,000), manifold: 90.4% ($1,000), manifold: 74.8% ($170), manifold: 20.1% ($100)
No comments yet. Be the first to share your reasoning.
Sign in to join the discussion
The FDA must approve any GLP-1 receptor agonist (e.g., semaglutide, tirzepatide, or similar) for over-the-counter sale without a prescription before January 1, 2028. Based on official FDA approval announcements.
Sign in to make predictions, track your accuracy, and compete on the leaderboard.
Sign in to predictLive update (market_pulse): market consensus shifted. Sources: manifold: 57.0% ($1,000), manifold: 90.4% ($1,000), manifold: 74.8% ($170), manifold: 20.1% ($100)
No comments yet. Be the first to share your reasoning.
Sign in to join the discussion